^
    Back
    Association details:
    Biomarker:SSTR positive
    Cancer:Neuroendocrine Tumor
    Regimen:
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

    Published date:
    09/29/2023
    Excerpt:
    PRRT for SSTR-positive tumors, chemotherapy (eg, CAPTEM), everolimus, or sunitinib are recommended as second- or later-line therapy for patients with G1-G2 panNETs, with choice of therapy depending on patient characteristics and goals of treatment…